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Abstract 
Purpose: To investigate the effect of the Ma-Xin-Di-Tan (MXDT) decoction on ovalbumin-induced 
allergic asthma (AA) in mice. 
Methods: Asthma was induced in mice by ovalbumin (OVA) injection, and different doses of MXDT 
(150, 300, and 600 mg/kg/day) were administered orally for 28 days. Pathological changes in lung 
tissues were examined, while levels of cytokines, including interleukin (IL)-4, IL-6, IL-17, interferon 
(IFN)-γ, and transforming growth factor (TGF)-β, were determined using enzyme-linked immunosorbent 
assays (ELISAs) of the bronchoalveolar lavage fluid. Toll-like receptor (TLR)-4, GATA-binding protein 
(GATA)-3, Ox40 ligand (OX40L), indoleamine 2,3-dioxygenase (IDO), forkhead box P3 (Foxp3), and T 
box expressed in T cells (T-bet) levels were determined in lung tissues by western blot analysis. 
Results: MXDT inhibited the inflammatory reaction of lung tissues in OVA-challenged mice. After 
treatment with MXDT, levels of IL-4, IL-6, IL-17, and TGF-β were downregulated, whereas IFN-γ levels 
were upregulated. In addition, MXDT decreased TLR-4, GATA-3, and OX40L levels in lung tissues but 
increased the expression of Foxp3, T-bet, and IDO.  
Conclusion: MXDT has antiallergic effects on OVA-induced AA in mice; the possible molecular 
mechanisms might involve the inhibition of inflammatory reactions and modulation of Th1/Th2 cytokine 
balance. 
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Allergic asthma (AA), characterized by serious 
airway inflammation, airway hyperreactivity, 
shortness of breath, and excessive mucous 
production in pulmonary airways, is a common 
and intractable allergic disorder that affects the 
life quality for millions of individuals [1-3]. It is 
estimated that AA affects more than 300 million 
patients worldwide, with an increasing 
prevalence in recent years [4,5]. Currently 
available drugs, such as glucocorticoids, can 
only temporary control or relieve asthma 
symptoms, and long-term usage of such drugs 
can result in serious adverse reactions [2,5]. 
Thus, more effective therapies for AA are 
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It has been reported that traditional herbal 
medicines are a potential source of effective 
agents for the treatment of allergic diseases, 
including AA, allergic rhinitis, and eczema [2,6,7]. 
The Ma-Xin-Di-Tan (MXDT) decoction is derived 
from the clinical experiences of Professor Jianer 
Yu in the treatment of AA (Shanghai Municipal 
Hospital of Traditional Chinese Medicine, 
Shanghai, China). MXDT is mainly composed of 
the whole Ephedra sinica Stapf herb, the seeds 
of Amygdalus Communis Vas, rainworm, and the 
seeds of Prunus persica (L.) Batsch. In the 
present study, the antiallergic effects of the Ma-
Xin-Di-Tan decoction on ovalbumin (OVA)-
induced AA was evaluated in mice, and its 




Chemicals and reagents 
 
All herbal medicines were purchased from the 
Shanghai traditional Chinese medicine company 
(Shanghai, China). Dexamethasone (Dex) and 
aluminum hydroxide were obtained from Sigma-
Aldrich (Shanghai, China). Commercial enzyme-
linked immunosorbent assay (ELISA) kits for 
interleukin (IL)-4, IL-6, IL-17, interferon (IFN)-γ, 
and transforming growth factor (TGF)-β were 
purchased from Bioswamp Co. (Shanghai, 
China). PVDF membranes were purchased from 
Millipore Biotech (MA, USA). All antibodies used 
in this research, including those against Toll-like 
receptor (TLR)-4, GATA-binding protein (GATA)-
3, Ox40 ligand (OX40L), indoleamine 2,3-
dioxygenase (IDO), forkhead box P3 (Foxp3), 
and T box expressed in T cells (T-bet), were 





A total of 60 mice (18 – 22 g) were obtained from 
the Shanghai Laboratory Animal Research 
Center (Shanghai, China). All animals received 
humane care according to the Declaration of 
Helsinki, which was promulgated in 1964 and 
amended in 1996 [8]. All experimental protocols 
were approved by the Animal Care and Use 
Committee of Shanghai Municipal Hospital of 
Traditional Chinese Medicine, Shanghai, China 
(approval no. a201611-27#). Mice were randomly 
divided into six groups (n = 10): normal group, 
control group (AA mice), positive drug treatment 
group (Dex), and three MXDT treatment groups 
(150, 300, and 600 mg/kg/day). The 
experimental protocol was carried out according 
to previous reports with some modifications [2,9]. 
The mice in the control, Dex, and MXDT groups 
were immunized intraperitoneally with a mixture 
of 50 mg OVA and 2 mg aluminum hydroxide on 
days 1 and 14. Subsequently, on days 21 
through 28, the mice were challenged with a 5 % 
OVA solution for 40 min using an ultrasonic 
nebulizer (OMRON Co, Tokyo, Japan). The Dex 
(1.5 mg/kg/day) and MXDT (150, 300, and 600 
mg/kg/day) groups were administered agents 
orally on days 28 through 56. Twenty-four hours 
after the final drug treatment, the mice were 
sacrificed by cervical dislocation, and the 
bronchoalveolar lavage fluid (BALF) and lung 





Lungs tissues were fixed in 10 % 
paraformaldehyde for 24 h, then embedded in 
paraffin and subsequently sectioned (5-μm-thick 
slices). The lung tissue sections were 
subsequently stained with hematoxylin and eosin 
for routine histochemical analysis. Finally, 
pathological changes in the lung tissues were 
examined using an optical microscope (Olympus 




The levels of IL-4, IL-6, IL-17, IFN-γ, and TGF-β 
were quantified in the supernatant of the BALF 
with commercial ELISA kits following the 
manufacturer’s instructions. 
 
Western blot analyses 
 
Lung tissues were homogenized in lysis buffer. 
Total protein was then extracted from the lung 
tissues. Subsequently, 35 μg total lung tissue 
protein were separated by sodium 
dodecylsulfate-polyacrylamide gel electropho-
resis and transferred to a PVDF membrane, 
which was then probed with primary antibodies 
against TRL-4, GATA-3, OX40L, IDO, Foxp3, 
and T-bet. The PVDF membrane was incubated 
with horseradish peroxidase-conjugated 
secondary antibodies. The target protein bands 
were then visualized by chemiluminescence, and 




Data are presented as the mean ± standard 
deviation (SD). Statistical comparisons were 
made by one-way analysis of variance using 
SPSS software (version 18.0, USA), followed by 
Dunnett’s multiple comparison test. A P value 
less than 0.05 was considered statistically 
significant. 






MXDT treatments alleviate inflammatory 
reactions in lung tissues of OVA-challenged 
mice 
 
Results of the pathological examinations of the 
lung tissues are shown in Figure 1. In normal 
mice, bronchial wall tissues were normal and the 
structural integrity was intact; no obvious 
pathological changes were observed (Figure 1A). 
In contrast, in the control mice, the bronchial 
walls appeared thick and damaged, and the 
airway lumen was obviously narrower; 
inflammatory cell infiltration could be observed in 
the airway walls and other lung tissues (Figure 
1B). Interestingly, for Dex- and MXDT-treated 
mice, the inflammatory and pathological changes 
mentioned above had been significantly 
alleviated; no obvious bronchial wall thickening 
was observed, but moderate inflammatory cell 





Figure 1: Pathological examination of lung tissues (magnification: ×200). A – F represents the normal, control, 





Figure 2: Cytokines levels in BALF. All drugs were administered orally for 28 days. Data are expressed as the 
mean ± SD (n = 10); **p < 0.01 compared to controls 
 
MXDT treatments regulate cytokine levels in 
the BALF of OVA-challenged mice 
 
Results of the ELISAs are shown in Figure 2. 
The cytokine levels of IL-4 (P < 0.01), IL-6 (P < 
0.01), IL-17 (P < 0.01), and TGF-β (P < 0.01) 
were significantly higher in the BALF of control 
mice than in that of normal mice; however, the 
cytokine levels of IFN-γ (P < 0.01) were 
significant decreased in the BALF of control mice  





Figure 3: TLR-4 expression in the lung tissues of OVA-challenged mice. The protein expression levels were 
determined using western blot assays. All drugs were administered orally for 28 days. Data are expressed as the 




Figure 4: GATA-3, OX40L, IDO, Foxp3, and T-bet expression levels in the lung tissues of OVA-challenged mice. 
Protein expression was determined using western blot assays. All drugs were administered orally for 28 days. 
Data are expressed as the mean ± SD (n = 10); **p < 0.01, compared to controls 
 
compared to in that of normal mice. Interestingly, 
after treatment with MXDT (150, 300, and 600 
mg/kg/day) for 28 days, the increased levels of 
IL-4 (p < 0.01), IL-6 (p < 0.01), IL-17 (p < 0.01), 
and TGF-β (p < 0.01) were downregulated, 
whereas the decreased levels of IFN-γ (p < 0.01) 
were upregulated, compared to control mice. 
 
Effect of MXDT treatments on protein 
expression  
 
Results  of  western  blot  assays  are  shown  in  
Figure 3 and Figure 4. The results showed that 
after stimulation with OVA, the protein 
expression levels of TLR-4 (Figure 3) (p < 0.01), 
GATA-3 (p < 0.01), and OX40L (p < 0.01) (Figure 
4) in lung tissues were significantly upregulated 
compared with those of normal mice, whereas 
Foxp3 (p < 0.01), T-bet (p < 0.01), and IDO (P < 
0.01) (Figure 4) expression was downregulated 
(P < 0.01). However, compared with control 
mice, treatment of OVA-challenged mice with 
MXDT decreased the upregulated expression 
levels of TLR-4 (p < 0.01) (Figure 3), GATA-3 (p 
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< 0.01), and OX40L (p < 0.01) (Figure 4) in lung 
tissues and increased the downregulated 
expression levels of Foxp3 (p < 0.01), T-bet (p < 




To the best of our knowledge, the present report 
is the first animal research study to describe the 
anti-allergic effects of the MXDT decoction on 
ovalbumin-induced AA in mice. Animal models 
are a very important tool to explore human 
disease pathology and identify more useful and 
effective drugs to treat human diseases.  
 
 
The mouse model of OVA-challenged AA is a 
broadly used tool for the investigation of asthma 
and for the screening of candidate antiasthma 
drugs [10,11]. Thus, the present study 
successfully induced AA in mice after treatment 
with OVA. Inflammatory reactions play important 
roles in the development of AA, and various 
studies have demonstrated that the alleviation of 
inflammatory reactions is a useful way to treat 
asthma [12,13]. The present results demonstrate 
that MXDT inhibits inflammatory reactions in lung 
tissues of mice with OVA-induced AA. 
 
Th1/Th2 balance is recognized as an important 
mediator of asthma; modulation of Th1/Th2 
balance is thus considered beneficial for the 
treatment of asthma [2,14,15]. The present study 
revealed that after treatment with MXDT, 
increased levels of Th2 cytokines (IL-4 and IL-6) 
were downregulated, whereas decreased levels 
of the Th1 cytokine IFN-γ was upregulated, 
suggesting that MXDT can modulate Th1/Th2 
balance. Clinical research has reported high 
serum/BALF levels of IL-7 and TGF-β in asthma 
patients [16,17].  
 
IL-17 is an early proinflammatory cytokine that 
can activate TGF-β; these two cytokines can 
then cause proinflammatory cytokine release, 
airway inflammation, goblet cell proliferation, and 
airway remodeling [16,17]. The present results 
show that MXDT is able to decrease the levels of 
IL-7 and TGF-β in the BALF of mice with OVA-
induced AA. TLR4, an important pattern 
recognition receptor, plays a crucial role in the 
reactions and secretion of inflammatory 
cytokines. The ratio of GATA-3, OX40L, and T-
bet levels was reported to be important for 
Th1/Th2 balance. GATA-3 and OX40L may 
activate the release of Th2 cytokines, whereas T-
bet commonly activates the release of Th1 
cytokines [18-20]. The relative increase in GATA-
3 levels may also moderate Th1/Th2 balance 
[19,20]. In addition, IDO and Foxp3 are 
reportedly able to alleviate the allergic symptoms 
of AA patients [21,22]. The results of the present 
study suggest that MXDT can moderate Th1/Th2 
balance by regulating TRL-4, GATA-3, OX40L, 




The present results suggest that MXDT has 
potential anti-allergic effects on OVA-induced AA 
in mice; possible molecular mechanisms may 
involve the inhibition of inflammatory reactions 
and the modulation of Th1/Th2 balance. The 
present work implies that MXDT is a promising 
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